(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2...at in spite of depression being common among long-... treated//. "Stroke patients suffering from depre...ife and a higher rate of death, so it is important...stroke," study lead author Seana L. Paul, a resear...
...moderate asthma who were treated with anti-tumor n...nal antibody, experienced significantly// fewer di...ebo. This research appears in the first issue for ...f Respiratory and Critical Care Medicine, publishe...
...he big time killer AIDS/ HIV infection worldwide C...arheaded// by Dr Benigno Rodriguez M.D and his ext...ve presented their latest findings in the current ... Current therapeutic guidelines have been question...
... due to Japanese encephalitis, the death toll sinc...trict.// According to the Additional Director (He...ing illness have been reported from several parts ... Wednesday evening. Mr. Prasad said that 74 peopl...
Other Medicine News:Health News:Monoclonal Antibody Reduces Exacerbations in Asthmatics 2(Date:9/4/2008)... SAN MATEO, Calif., Sept. 4 /PRNewswire-FirstCa...y announced that the pivotal clinical study of,Pol...s partner, Chemische,Fabrik KREUSSLER & Co. GmbH (...point and has been submitted to FDA as part of a N...l clinical study, named the EASI (Efficacy and saf...
(Date:9/4/2008)... Pivotal Study Seeks to Enroll 750 Women at More T.... 4 /- QuatRx Pharmaceuticals, a,priv...velopment and,commercialization of compounds to tr...ers, today announced that it has initiated a secon... tablets), the company,s,estrogen-free oral therap...
(Date:9/4/2008)... Data Announcements Remain on Schedule with Two ... Clinical Data Release in November 2008, BRIDGEWA...ceuticals,Inc., a specialty pharmaceutical compan...etabolic disease, today announced the appointment ... of directors., Peter Garrambone,s career include...
(Date:9/3/2008)... - Long term follow up results from chronically...d exceed positive data obtained earlier in 2008, ...ificant and long-term antiviral effect of t...the way and strongly support move into a second ge...uvant IC31(R) acting through TLR ...
Breaking Medicine Technology:338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Batman Takes on Gotham City With a Little Help From Milk 20428 1Batman Takes on Gotham City With a Little Help From Milk 20428 2Texas Jury Awards 24250 Million Patent Infringement Verdict Against Boston Scientific in Balloon Catheter Lawsuit 20425 1Texas Jury Awards 24250 Million Patent Infringement Verdict Against Boston Scientific in Balloon Catheter Lawsuit 20425 2Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen New Survey Reveals 20422 1Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen New Survey Reveals 20422 2Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen New Survey Reveals 20422 3Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen New Survey Reveals 20422 4Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen New Survey Reveals 20422 5Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen New Survey Reveals 20422 6New Research and Treatment Options for Millions Suffering Headaches and Chronic Pain to be Presented at 10th Annual Headache and Pain Conference 20419 1New Research and Treatment Options for Millions Suffering Headaches and Chronic Pain to be Presented at 10th Annual Headache and Pain Conference 20419 2New Research and Treatment Options for Millions Suffering Headaches and Chronic Pain to be Presented at 10th Annual Headache and Pain Conference 20419 3...ISING-WEIHENSTEPHAN, Germany, June 21, 2007 /PRNew...developing Anticalins(R), a,novel class of targete... its proprietary Duocalin(R) technology has succes...mmenting on this development, Dr Andreas Hohlbaum,...f Pieris said: "As Pieris,continues to validate th...
...NTAIN VIEW, Calif., June 22, 2007 /PRNewswire/ -- ...will present Phase 2,data from its Unit Dose Budes...ram at the World Asthma Meeting at the Lutfi Kirda...rkey. , The oral and poster presentation entitled,...e formulation of budesonide for,nebulized delivery...
Other Medicine Technology:Pieris Progresses Development of its Proprietary Biotherapeutics,Platform: Successful Demonstration of Dual Targeting With,Duocalin(R) Technology 2Pieris Progresses Development of its Proprietary Biotherapeutics,Platform: Successful Demonstration of Dual Targeting With,Duocalin(R) Technology 3MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2,Clinical Data at the World Asthma Meeting 2...e DexCom STS Continuous Glucose Monitoring System ...elessly transmits blood glucose readings to the De...ludes a wirelike sensor which is inserted via the ...t under the skin where it is held in place by an a...
...rdioVault combines proven Eclipse,Plus or 850 EC...capability. Doctors,maintain all the benefits of...he,ability to view and access diagnostic-quality...iagnostic-quality viewing and printing,either f...
For practices performing routine Holter,monitoring, the Burdick Vision Holter,System with QuickStep Wizard provides a,practical, no-nonsense diagnostic tool ideal,for todays tightly managed h
For practices that need an advanced Holter,monitoring solution, the Burdick Vision,Premier Holter System provides a powerful,diagnostic tool. The Vision Premier system,adds expanded viewing c
Medicine Products: